Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
Bellofiore C, Benvenuti P, Mina R, Basset M, Foli A, Nanci M, Nuvolone M, Guida G, Attanasio A, Mussinelli R, Mangiacavalli S, Cartia CS, Masoni V, Palumbo M, Cani L, Oliva S, Consoli U, Conticello C, Di Raimondo F, Arcaini L, Bringhen S, Merlini G, Palladini G, Milani P. Bellofiore C, et al. Hematol Oncol. 2024 Jul;42(4):e3289. doi: 10.1002/hon.3289. Hematol Oncol. 2024. PMID: 38824453
Development and Validation of Staging Systems for AA Amyloidosis.
Basset M, Schönland SO, Obici L, Günther J, Riva E, Dittrich T, Milani P, Ferretti VV, Pasquinucci E, Foli A, Kimmich C, Nanci M, Bellofiore C, Benigna F, Beimler J, Benvenuti P, Fabris F, Mussinelli R, Nuvolone M, Klersy C, Albertini R, Merlini G, Hegenbart U, Palladini G, Blank N. Basset M, et al. Among authors: bellofiore c. J Am Soc Nephrol. 2024 Jun 1;35(6):782-794. doi: 10.1681/ASN.0000000000000339. Epub 2024 Mar 21. J Am Soc Nephrol. 2024. PMID: 38512269 No abstract available.
A Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy.
Bulla A, Markovic U, Bellofiore C, Stella S, Conticello C, DI Raimondo F, Stagno F. Bulla A, et al. Among authors: bellofiore c. Cancer Diagn Progn. 2021 Mar 3;1(1):19-22. doi: 10.21873/cdp.10003. eCollection 2021 Mar-Apr. Cancer Diagn Progn. 2021. PMID: 35399694 Free PMC article.
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Markovic U, Romano A, Del Fabro V, Bellofiore C, Bulla A, Parisi MS, Leotta S, Gentile M, Cangialosi C, Vincelli I, Mineo G, Rossi M, Poidomani M, Uccello G, Maugeri C, Mannina D, Innao V, Di Raimondo F, Conticello C. Markovic U, et al. Among authors: bellofiore c. Front Oncol. 2021 Mar 5;11:624405. doi: 10.3389/fonc.2021.624405. eCollection 2021. Front Oncol. 2021. PMID: 33763359 Free PMC article.
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment.
Bellofiore C, Sapienza G, Markovic U, Del Fabro V, Romano A, Stagno F, Tamburino C, Mangiafico S, Di Raimondo F, Conticello C. Bellofiore C, et al. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):e456-e459. doi: 10.1016/j.clml.2020.12.022. Epub 2020 Dec 26. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33531286 No abstract available.
12 results